Cargando…
Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects
INTRODUCTION: The aims of this study were to characterize the multiple-dose pharmacokinetics (PK) of ozanimod’s major active metabolites (CC112273 and CC1084037) and to evaluate the pharmacodynamic and PK interactions with pseudoephedrine (PSE). METHODS: In this phase 1, single-center, randomized, d...
Autores principales: | Tran, Jonathan Q., Zhang, Peijin, Walker, Susan, Ghosh, Atalanta, Syto, Mary, Wang, Xiaomin, Harris, Sarah, Palmisano, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595987/ https://www.ncbi.nlm.nih.gov/pubmed/33025342 http://dx.doi.org/10.1007/s12325-020-01500-0 |
Ejemplares similares
-
Concentration‐QTc Modeling of Ozanimod’s Major Active Metabolites in Adult Healthy Subjects
por: Briggs, Emily, et al.
Publicado: (2021) -
Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers
por: Flanagan, Shawn, et al.
Publicado: (2018) -
Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016) -
Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019) -
Effects of High‐ and Low‐Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator
por: Tran, Jonathan Q., et al.
Publicado: (2017)